Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

7.78
+0.750010.67%
Post-market: 7.64-0.1400-1.80%19:54 EST
Volume:13.00M
Turnover:100.19M
Market Cap:1.69B
PE:-5.48
High:8.00
Open:6.99
Low:6.99
Close:7.03
52wk High:16.44
52wk Low:5.79
Shares:217.69M
Float Shares:191.00M
Volume Ratio:0.82
T/O Rate:6.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4203
EPS(LYR):-1.4203
ROE:-54.85%
ROA:-26.66%
PB:2.59
PE(LYR):-5.48

Loading ...

Ocular Therapeutix Is Maintained at Buy by Needham

Dow Jones
·
Feb 20

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ocular Therapeutix (OCUL) and Sanofi (SNY)

TIPRANKS
·
Feb 20

Ocular Therapeutix Is Maintained at Buy by Chardan Capital

Dow Jones
·
Feb 18

Stock Track | Ocular Therapeutix Plunges 7.15% in Post-Market as Wet AMD Trial Data Disappoints Investors

Stock Track
·
Feb 18

NASD Most Active Issues

Dow Jones
·
Feb 18

U.S. Small Caps Close Mixed As ZIM Integrated Shipping Leads, Ocular Therapeutix Lags

Dow Jones
·
Feb 18

Ocular Therapeutix selloff brings attractive entry point, says Citizens

TIPRANKS
·
Feb 18

Ocular Therapeutix Down Over 25%, on Pace for Largest Percent Decrease Since October 2021 -- Data Talk

Dow Jones
·
Feb 18

Analysts Offer Insights on Healthcare Companies: Cybin (HELP) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Feb 18

Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating

TIPRANKS
·
Feb 17

Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff

TIPRANKS
·
Feb 17

Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes

Benzinga_recent_news
·
Feb 17

Stock Track | Ocular Therapeutix Plunges 22.31% Pre-market Despite Positive Phase 3 Trial Results for Wet AMD Drug

Stock Track
·
Feb 17

Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint

TIPRANKS
·
Feb 17

Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's Eylea

Reuters
·
Feb 17

Ocular Therapeutix Shares Down 27% Premarket After Co Reports Late‑Stage Eye‑Disease Trial Data

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix Reports Positive Phase 3 Results for AXPAXLI in Wet AMD

Reuters
·
Feb 17

Ocular Therapeutix: Complementary Sol-R Phase 3 Non-Inferiority Trial of Axpaxli in Wet Amd to Continue as Planned, Topline Data Expected Q1 2027

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix Inc - Plans to Submit Nda Based on Sol-1 Data

THOMSON REUTERS
·
Feb 17

Ocular Therapeutix Inc - Axpaxli Well-Tolerated With No Ocular Saes in Sol-1

THOMSON REUTERS
·
Feb 17